Home » Topics » BioWorld Science, Respiratory

BioWorld Science, Respiratory
RSS

Moderna and Vertex enter new collaboration to develop gene-editing therapies for CF

Sep. 18, 2020

AVM receives FDA clearance to study AVM-0703 for COVID-19- and influenza-related ARDS

Sep. 17, 2020

First patient dosed in phase II study of GC-4419 for COVID-19

Sep. 17, 2020

Profiling of JAK inhibitors AZD-4604 and AZD-0449 in translational rodent model of asthma

Sep. 15, 2020

FDA approves Trelegy Ellipta for asthma

Sep. 14, 2020

Phase III trial of Fasenra in nasal polyposis meets coprimary endpoints

Sep. 14, 2020

QBW-251: a CFTR potentiator in phase II for the treatment of COPD

Sep. 14, 2020

Results from a phase IIa POC trial of the oral adenosine A1 receptor antagonist PBF-680

Sep. 9, 2020

First phase I data presented for the neutrophil elastase inhibitor BI-1323495

Sep. 9, 2020

New personalized cystic fibrosis treatment treats Class V mutations

Sep. 9, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...